Chronic Migraine clinical trials

Explore recruiting chronic migraine clinical trials.

Recruiting chronic migraine studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Migraine trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C4951013 - AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE

Hungary, Italy, Spain, Czechia, Poland, Finland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized placebo-controlled double-blind phase III two-arm study to investigate the reduction of Monthly Migraine Days (MMDs) over 12 weeks of treatment with combination of CGRP mAbs and onabotulinumtoxin A intramuscularly compared with CGRP mAbs and placebo in male and female participants with chronic migraine aged 18-70 years.

Norway

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Poland, Hungary, Italy, Netherlands, Denmark, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of eptinezumab for the preventive treatment of migraine

Poland, Slovakia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in chronic migraine

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants

Italy, Poland, Spain, Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Chronic Migraine trials by city

Chronic Migraine in Toronto Chronic Migraine in Vancouver Chronic Migraine in Montreal Chronic Migraine in Calgary Chronic Migraine in Edmonton Chronic Migraine in Ottawa Chronic Migraine in Winnipeg Chronic Migraine in Quebec City Chronic Migraine in Hamilton Chronic Migraine in Kitchener Chronic Migraine in London Chronic Migraine in Halifax Chronic Migraine in New York Chronic Migraine in Los Angeles Chronic Migraine in Chicago Chronic Migraine in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease